Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.
Prime Medicine has raised $5.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in August 2025.
Prime Medicine's investors include ARCH Venture Partners, Samsara BioCapital, Redmile Group, Cormorant Asset Management, Casdin Capital.
Prime Medicine is headquartered in Cambridge, United States.
Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.
Prime Medicine is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Prime Medicine — Funding & Investors." VCBacked, August 1, 2025, https://www.vcbacked.co/company/prime-medicine. Accessed July 19, 2026.
VCBacked. (2025). Prime Medicine — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/prime-medicine
{{cite web |title=Prime Medicine — Funding & Investors |url=https://www.vcbacked.co/company/prime-medicine |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated